United States Patent 8,269,040 Coverage Analysis: Scope, Claims, and US Patent Landscape for O-Desmethylvenlafaxine Succinate Hydrate (Monohydrate)
Executive summary: US Patent 8,269,040 is a narrow, compound-centric US claim set limited to O-desmethylvenlafaxine succinate in hydrate form, with a dependent claim specifically covering the monohydrate. The practical enforcement and freedom-to-operate (FTO) impact is driven by whether a product uses succinate salt and whether the solid form is a hydrate that matches the claimed hydrate identity. The patent’s enforceable scope is not a method, not a formulation dosage form, and not a broader class of venlafaxine metabolites. It is strongest against products where the drug substance is isolated and supplied as O-desmethylvenlafaxine succinate hydrate (and, for the dependent claim, specifically monohydrate).
What does US Patent 8,269,040 claim for O-desmethylvenlafaxine succinate hydrate?
Claim 1 (independent):
A compound that is O-desmethylvenlafaxine succinate, where the compound is a hydrate of O-desmethylvenlafaxine succinate.
Claim 2 (dependent):
The compound of claim 1 that is O-desmethylvenlafaxine succinate monohydrate.
What “O-desmethylvenlafaxine succinate hydrate” means in legal claim terms
The claim language collapses the scope into three elements that must all be present:
- Active chemical entity: O-desmethylvenlafaxine
- Salt form: succinate (not a different counterion)
- Solid-state condition: hydrate (specifically hydrated forms fall under claim 1; monohydrate falls under claim 2)
This structure makes the patent’s coverage fact-dependent on the drug substance solid form actually manufactured, tested, and marketed.
What the dependent claim adds
Claim 2 restricts claim 1 to a specific stoichiometric hydrate identity: monohydrate. That narrows the protected scope compared with claim 1, which includes hydrate forms beyond the monohydrate unless the intrinsic record limits “hydrate” to a specific structural/analytical definition.
How broad are the claims: does “hydrate” cover any stoichiometry or only specific solvates?
Short answer: The claim 1 language is broad in concept (“a hydrate”), but enforceability depends on how “hydrate” is defined in the specification and how the accused solid form is characterized.
Claim breadth by feature
- Salt identity is fixed: “succinate” is mandatory.
- Molecule identity is fixed: “O-desmethylvenlafaxine” is mandatory.
- Hydrate identity is not fixed to monohydrate in claim 1: any hydrate form could fall within claim 1 if the solid form is a hydrate “of O-desmethylvenlafaxine succinate.”
Practical scoping consequence
If a competitor markets:
- an anhydrous succinate (no water), it should not read on claim 1’s “hydrate” limitation;
- a different hydrate stoichiometry (e.g., dihydrate, hemihydrate) it still plausibly reads on claim 1 if it is treated as a “hydrate” of that salt;
- an ice-cold physical mixture where water is present but not as a hydrate solid form, claim interpretation depends on the solid-state definition in the patent record.
What analysis must focus on for claim construction
For litigation and FTO, the decisive question is not only whether a sample contains water, but whether it qualifies as a hydrate of that salt within the patent’s contemplated solid form definition (often tied to water uptake, crystallinity, DSC/TGA behavior, and XRPD patterning).
What is the enforceable scope: compound only or does it cover tablets, capsules, and formulations?
Short answer: Based on the claim set provided, the patent covers the compound (drug substance), not a particular finished dosage form.
Why dosage-form coverage is limited from the claim text
The claims are not framed as:
- a pharmaceutical composition,
- a method of treating,
- a method of manufacture,
- a formulation with excipients,
- or a specific particle size, polymorph, or delivery system.
So a manufacturer selling tablets containing the same active solid form may still face infringement if the claim reads on the compound as supplied in the commercial drug substance. But infringement theories will depend on:
- whether product solids include the claimed hydrate,
- whether the hydrate is preserved through blending, compression, coating, and storage,
- and whether the claim is interpreted to cover the isolated intermediate or the final marketed solid.
Practical enforcement pattern for hydrate patents
In practice, hydrate patents often drive disputes around:
- what is shipped from the API vendor (hydrate vs non-hydrate form),
- whether the hydrate converts during formulation,
- and what analytical methods confirm the solid-state form in the drug product.
What patent estate surrounds US 8,269,040 for O-desmethylvenlafaxine succinate hydrates in the US?
Critical limitation: Without the full patent record, including bibliographic details, application family members, priority data, and cited/related patents, a complete US landscape map cannot be produced from the claim text alone.
Given only the two claims, the most defensible landscape inference is structural:
- US 8,269,040 is a hydrate-specific US patent on a particular salt and its monohydrate.
- The likely estate neighbors (in general terms) in such scenarios are other solid-state form patents for:
- anhydrates,
- other hydrate stoichiometries,
- polymorphs of the succinate salt,
- or related salt forms of the same API.
However, naming those specific US patents would require the actual patent numbers and family members, which are not provided.
When does US 8,269,040 lose exclusivity or expire in the US?
Short answer: The expiration date cannot be calculated from the claim text alone. Expiry depends on:
- filing date,
- non-provisional vs provisional timeline,
- patent term adjustment (PTA) and potential reductions,
- any terminal disclaimer,
- and whether the patent is still active (maintenance fees).
The claims provided do not include filing/priority details, and the patent number alone is not enough to compute accurate term and adjustments without the bibliographic record.
What is the Orange Book status of a product that uses O-desmethylvenlafaxine succinate monohydrate?
Short answer: Orange Book status cannot be determined from the claim text alone. Orange Book listing is tied to:
- a specific NDA/ANDA/BLA,
- the branded or generic product referencing the active ingredient,
- and the FDA listing of patents by patent number and expiration.
No NDA/ANDA/basis is provided here, so the Orange Book linkage cannot be stated.
What generic entry risks exist for O-desmethylvenlafaxine succinate hydrate monohydrate products?
Even without the full landscape, the claim structure indicates the principal generic entry risk vectors:
Risk vector 1: API is manufactured and shipped as the claimed hydrate
If the generic’s API is produced as O-desmethylvenlafaxine succinate hydrate and remains hydrated through shipping and blending, claim 1 is at risk.
Risk vector 2: API is specifically monohydrate
If the generic’s API is monohydrate, claim 2 is at direct risk.
Risk vector 3: hydrate conversion during development and stability
A common mitigation strategy is to qualify:
- an anhydrous succinate form, or
- an alternative hydrate form not meeting the “monohydrate” identity,
- or a form that converts to an unclaimed solid state under product conditions.
But that mitigation succeeds only if the commercial product solid state is demonstrably outside the claimed definitions.
How does US 8,269,040 compare with other solid-state patents for venlafaxine metabolites?
Short answer: From the claims provided, US 8,269,040 is narrower than patents that claim:
- a broader range of salt forms,
- polymorphic sets,
- general hydrates without specifying salt identity,
- methods of forming the solid state,
- or therapeutic use.
Because claim scope is anchored to succinate and O-desmethylvenlafaxine, the competitive gap is mostly about other solid-state forms of the same salt and hydrate status.
What formulations are protected by US 8,269,040 and how do polymorph/hydrate switching affect infringement?
Short answer: The claims provided protect the hydrate compound, not a specific formulation. But formulation development can still create infringement exposure if the marketed API or drug product contains the claimed hydrate at relevant points.
Typical solid-state switching pathways that change legal risk
- Switching from hydrate to anhydrous: likely avoids the “hydrate” limitation in claim 1.
- Switching from monohydrate to another hydrate: likely avoids claim 2 but not necessarily claim 1.
- Switching counterion from succinate to another salt: avoids both claim 1 and claim 2.
Analytical evidence that matters in disputes
For enforceability, companies typically build evidentiary packages around:
- Karl Fischer water content,
- TGA/DSC,
- XRPD for crystalline identity,
- and comparative spectra to confirm “monohydrate” vs other hydrates.
What patent litigation affects US 8,269,040?
Short answer: Litigation status cannot be determined from the claim text. It requires docket-level data tied to the patent number and the parties.
Key takeaways
- US 8,269,040 is a solid-state compound patent covering O-desmethylvenlafaxine succinate hydrates (claim 1) and specifically O-desmethylvenlafaxine succinate monohydrate (claim 2).
- The claims are narrow: they require both the succinate salt and a hydrate condition; claim 2 adds monohydrate identity.
- Formulation and manufacturing only matter to infringement insofar as they determine whether the API and/or marketed solid state retains the claimed hydrate identity.
- A credible generic or challenger strategy focuses on solid-state form control: anhydrate vs hydrate stoichiometry vs alternative counterions.
FAQs
-
Does a product containing O-desmethylvenlafaxine succinate hydrate but in a different stoichiometry infringe claim 2?
Claim 2 requires monohydrate. Different stoichiometry would not satisfy the monohydrate limitation.
-
Would anhydrate O-desmethylvenlafaxine succinate infringe claim 1?
Claim 1 requires that the compound is a hydrate. Anhydrate should not meet the hydrate limitation.
-
Do excipients or tablets/capsules change whether US 8,269,040 is infringed?
The claims are to a compound. Excipients matter only through whether the solid state present in the product meets the claimed hydrate identity.
-
Can a generic avoid liability by making the API in hydrate form but converting it during formulation?
Risk depends on whether the final marketed solid state contains the claimed hydrate (and whether it is monohydrate). Solid-state conversion evidence is central.
-
Is US 8,269,040 limited to specific polymorphs of the succinate hydrate?
Based on the claim text provided, the claims require a hydrate of the succinate, not a named polymorph set. The degree of polymorph restriction depends on the specification and claim construction.
References
- United States Patent 8,269,040, claims 1-2 (O-desmethylvenlafaxine succinate hydrate; monohydrate).
